Forecast
The analysts' average price target is €8.20 (+187.72%). The median is €8.20 (+187.72%).
| Buy |
4 |
| Hold |
0 |
| Sell |
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Entera Bio gets shortened FDA approval pathway for oral osteoporosis drug EB613
The FDA has agreed to a shortened approval study design for EB613: a 12-month, double-blind, placebo-controlled Phase III trial instead of the originally planned 24 months. Entera Bio raised $275 million and plans to begin recruitment in 2026. EB613 is an oral teriparatide tablet targeting patients who refuse injectable therapies; in Phase II it showed total-hip BMD increases of 1.34–1.57% after six months. Despite the milestone, the stock fell sharply on the conference day as investors remain cautious pending additional efficacy and safety data. » More on de.investing.com
Entera Bio posts wider Q2 loss as it ramps R&D ahead of EB613 Phase 3
Entera Bio reported a Q2 net loss of $7.3 million, or $0.14 per share, versus analyst expectations of a $0.09 per-share loss, driven by a $2.7 million non-cash warrant remeasurement and higher R&D spending. R&D rose to $3.2 million as the company prepares registrational work for its oral osteoporosis candidate EB613 after reaching FDA alignment on a 12-month Phase 3 design. Entera plans to start the pivotal trial in late 2026 with topline results targeted in H2 2028 and completed a $275 million private placement expected to extend its cash runway into 2030 (cash was $11.3 million at June 30). » More on finance.yahoo.com
Entera Bio secures $10 million in private placement led by BVF Partners
Entera Bio completed a private placement of approximately $10 million, issuing 7,827,789 units at $1.2775 each; each unit includes a common share or a pre-funded warrant and a five-year warrant to purchase 1.5 shares at $1.24. Gross proceeds are about $10 million; if the warrants are fully exercised, an additional roughly $14.5 million could be raised, bringing total potential proceeds to about $24.5 million. Entera intends to use the funds to start the pivotal Phase 3 trial of EB613 in postmenopausal women with osteoporosis and for working capital; the company notes a strong liquidity position (current ratio 6.94). The stock rose 26% last week and is currently trading at $1.22, though InvestingPro considers the shares overvalued at this level. » More on de.investing.com
Entera Bio secures $10 million private placement led by BVF Partners
Entera Bio completed a private placement of approximately 7,827,789 units at $1.2775 each, led by funds affiliated with BVF Partners, expected to generate gross proceeds of about $10 million. Each unit consists of a common share or a prepaid warrant plus a five-year warrant to purchase 1.5 common shares at $1.24; if fully exercised, additional proceeds of roughly $14.5 million could be raised (potential total proceeds ~ $24.5 million). The proceeds are intended to fund the phase 3 study of EB613 for the treatment of postmenopausal osteoporosis and for general corporate purposes; the securities are being offered pursuant to Section 4(a)(2). » More on de.investing.com
Entera Bio to file phase‑3 protocol for EB613 in Q1 2026
Entera Bio will submit the final phase‑3 protocol for EB613, an oral PTH tablet for osteoporosis, to the FDA in Q1 2026. The filing follows the FDA’s December 2025 recognition of bone mineral density (BMD) as an approval‑relevant endpoint. The company expects results from an ongoing phase‑1 bridging study of the next‑gen formulation by the end of Q1 2026 and plans to accelerate development of EB612 for hypoparathyroidism in 2026. According to analysis, Entera shows a high current ratio of 10.83 and is in talks about strategic partnerships, but remains a loss‑making and volatile biotech stock. » More on de.investing.com
Financials
In the last quarter, ENTERA BIO IS-,0000769 had revenue of €0 and net profit of -€13.77M
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | 100.00% |
| Net profit | -13.77M | 404.98% |
| EBITDA | -6.41M | 135.51% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €517.36M |
Number of shares | 174.14M |
52-week high/low | €3.83 - €0.83 |
| Dividends | No |
Beta | 1.46 |
P/E ratio | -8.39 |
PEG ratio | 0.19 |
P/B ratio | 1.72 |
P/S ratio | 0.00 |
Company profile
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
| Name | ENTERA BIO IS-,0000769 |
| CEO | Miranda J. Toledano |
| Headquarters | Jerusalem,
jm Israel |
| Website | |
| Sector | Consumer Staples |
| Industry | Food Products |
| IPO | 06/28/2018 |
| Employees | 27 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | ENTX |
Frankfurt | 5DT.F |
Düsseldorf | 5DT.DU |